Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS

NMR in Biomedicine

Volumn 15, Issue 2, 2002, Pages 99-105

  Beauregard, Daniel A ^a   Pedley, R Barbara ^b   Hill, Sally A ^c   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Combretastatin; DMXAA; Magnetic resonance imaging; Perfusion; Tumour

Indexed keywords

ACETIC ACID; DRUG PRODUCTS; MAGNETIC RESONANCE IMAGING; TUMORS;

SPECTROSCOPIC TECHNIQUE;

BIOMEDICAL ENGINEERING;

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; COMBRETASTATIN A4; GADOLINIUM PENTETATE; GLUCOSE; HYPNORM; MIDAZOLAM; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATE; PHOSPHORUS 31; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CELL ENERGY; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SCID MOUSE; TUMOR BLOOD FLOW; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, SCID; STILBENES; TRANSPLANTATION, HETEROLOGOUS; XANTHENES; XANTHONES;

EID: 0036200834     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.723     Document Type: Article

References (27)

1. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
2. Combined effects of angiostatin and ionizing radiation in antitumour therapy
3. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
4. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent
5. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
6. Changes in human tumour perfusion after DXMAA treatment, monitored by dynamic Gd-DTPA enhanced MRI
7. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues
8. The morphological effects of the anti-tumour agents flavone acetic acid and 5,6-dimethylxanthenone acetic acid on the colon 38 mouse tumour
9. Combretastatin A-4, an agent that displays a potent and selective toxicity toward tumour vasculature
10. Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours
11. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
12. Combretastatin A-4 phosphate as a tumor vascular targeting agent: Early effects in tumours and normal tissues
13. Stimulation of tumours to synthesise tumour necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
14. Recombinant tumor necrosis factor induces progoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1
15. Tumor necrosis factor α-induced vascular leakage involves PECAM1 phosphorylation
16. 99mTc-labeled HL-91; Prognox): Noninvasive detection of tumor 5,6-dimethylxanthenone-4-acetic acid
17. The susceptibility of tumors to the anti-vascular drug combretastatin A4 phosphate correlates with vascular permeability
18. Effects of combretastatin on murine tumours monitored by P31 MRS, H1 MRS and H1 MRI
19. Assessing tumor angiogenesis using macromolecular MR imaging contrast media
20. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
21. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: Magnetic resonance imaging of C6 rat glioma in nude mice
22. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI
23. Quantitative diffusion imaging in implanted human breast tumors
24. Phospholipid metabolites as indicators of cancer cell function
25. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents
26. 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: Effects of blood flow modification
27. Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice